相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- The University at Buffalo received $5 million from the State University of New York to lead a statewide, multi-campus research network on age-related brain disorders. - The award is part of $10 million in New York State funding supporting the SUNY Brain Institute, with UB designated anchoring hub for its inaugural module. - UB will serve as hub for three years, coordinating shared-access, governance, data-integration and operational infrastructure across five SUNY institutions. - The network aims to accelerate development of new biomarkers, therapeutic targets and approaches to diagnosis, treatment and prevention of neurological disease.
- Mentavi Health's online ADHD diagnostic evaluation demonstrated 80.6% sensitivity and 94.9% positive predictive value in a study of 345 adults published in the Journal of Clinical Psychiatry. - The digital assessment showed superior accuracy with only a 12% false-positive rate compared to 56% for traditional in-person clinical interviews. - This represents the first peer-reviewed validation of a fully digital diagnostic pathway for adult ADHD, addressing care gaps created by specialist shortages and six-month waiting lists. - The asynchronous online tool could improve access to ADHD diagnosis for rural, underserved, and shift-working populations who face geographic and scheduling barriers.
- Neurona Therapeutics has dosed the first patient in a Phase 1/2 clinical trial of NRTX-1001, a regenerative neural cell therapy for drug-resistant mesial temporal lobe epilepsy. - The therapy uses human stem cell-derived interneurons that secrete GABA to repair hyper-excitable neural networks, delivered as a single dose directly into the brain. - Initial results show remarkable efficacy with the first patient experiencing a dramatic reduction from approximately 30 seizures per month to just one or two seizures per month. - The treatment offers a potential non-destructive alternative to current invasive surgical options that remove or destroy brain tissue in epilepsy patients.
